Tyra Biosciences, Inc. (TYRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$22.01-17.66%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Report initial three-month complete response data by August 2026: Data reported 2026-09-09 vs 2026-08 target; 1d return -17.7%.
Tyra aims to report initial response data in August 2026. They plan safety data from a sentinel cohort by Q4 2026. New leadership brings industry experience. These steps could improve confidence in their cancer therapies.
Tyra is loss-making and missed recent earnings twice. Skepticism about their key drug SURF-302 is rising. The company faces competition and no clear revenue yet.
The market prices in ongoing losses and uncertainty. There is no clear consensus on revenue growth or fair value.
Breaks if: EPS losses worsen beyond -2.55 in FY26 or -2.82 in FY27
Breaks if: Initial response data is not reported by August 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state reflects uncertainty due to recent earnings misses and high risk, while management is focused on advancing clinical studies.
The market appears to have priced in a challenging outlook, given the company's loss-making status and recent earnings misses. Expectations may be low, especially as the company operates in a high-miss-rate industry.
Fundamentals are likely to remain under pressure in the near term, as the company has a significant probability of missing earnings expectations again. Management's focus on advancing clinical trials may provide some stability, but recent financial performance has been weak.
The long-term thesis hinges on the company's ability to deliver on clinical milestones and avoid further earnings misses. Additionally, the performance of sector bellwethers and the overall economic environment will play a crucial role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company faces challenges with its dabogratinib strategy. There is caution about the upcoming IR-NMIBC data and its 2027 readouts. An investor advised being careful with the interpretation of this data. This caution may impact expectations for future clinical progress.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management aims to report initial three-month complete response data from both dose cohorts in August 2026.
Breaks if: Safety sentinel results are not released by Q4 2026
In the next 1 to 3 years, TYRA's performance will depend on its clinical progress and the broader healthcare sector's momentum. Not investment advice.